Related references
Note: Only part of the references are listed.COVID-19 in Immunocompromised Hosts: What We Know So Far
Monica Fung et al.
CLINICAL INFECTIOUS DISEASES (2021)
Prolonged Severe Acute Respiratory Syndrome Coronavirus 2 Replication in an Immunocompromised Patient
Ji Hoon Baang et al.
JOURNAL OF INFECTIOUS DISEASES (2021)
Humoral and Cellular Responses to mRNA-1273 and BNT162b2 SARS-CoV-2 Vaccines Administered to Hemodialysis Patients
Jose Jesus Broseta et al.
AMERICAN JOURNAL OF KIDNEY DISEASES (2021)
Immunologic Testing for SARS-CoV-2 Infection from the Antigen Perspective
Dandan Li et al.
JOURNAL OF CLINICAL MICROBIOLOGY (2021)
What defines an efficacious COVID-19 vaccine? A review of the challenges assessing the clinical efficacy of vaccines against SARS-CoV-2
Susanne H. Hodgson et al.
LANCET INFECTIOUS DISEASES (2021)
BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting
Noa Dagan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Safety of the First Dose of SARS-CoV-2 Vaccination in Solid Organ Transplant Recipients
Brian J. Boyarsky et al.
TRANSPLANTATION (2021)
Risk of mortality in patients infected with SARS-CoV-2 variant of concern 202012/1: matched cohort study
Robert Challen et al.
BMJ-BRITISH MEDICAL JOURNAL (2021)
Reduced humoral response to mRNA SARS-CoV-2 BNT162b2 vaccine in kidney transplant recipients without prior exposure to the virus
Ayelet Grupper et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2021)
Impaired immunogenicity of BNT162b2 anti-SARS-CoV-2 vaccine in patients treated for solid tumors
J. Barriere et al.
ANNALS OF ONCOLOGY (2021)
Immunogenicity and safety of anti-SARS-CoV-2 mRNA vaccines in patients with chronic inflammatory conditions and immunosuppressive therapy in a monocentric cohort
Ulf M. Geisen et al.
ANNALS OF THE RHEUMATIC DISEASES (2021)
Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia
Yair Herishanu et al.
BLOOD (2021)
Serologic Response to Messenger RNA Coronavirus Disease 2019 Vaccines in Inflammatory Bowel Disease Patients Receiving Biologic Therapies
Serre-Yu Wong et al.
GASTROENTEROLOGY (2021)
Effectiveness of 2-Dose Vaccination with mRNA COVID-19 Vaccines Against COVID-19–Associated Hospitalizations Among Immunocompromised Adults — Nine States, January–September 2021
Peter J. Embi et al.
MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT (2021)
Antibody Response to 2-Dose SARS-CoV-2 mRNA Vaccine Series in Solid Organ Transplant Recipients
Brian J. Boyarsky et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2021)
BNT162b2 vaccination in heart transplant recipients: Clinical experience and antibody response
Yael Peled et al.
JOURNAL OF HEART AND LUNG TRANSPLANTATION (2021)
Low immunogenicity to SARS-CoV-2 vaccination among liver transplant recipients
Liane Rabinowich et al.
JOURNAL OF HEPATOLOGY (2021)
Safety and immunogenicity of one versus two doses of the COVID-19 vaccine BNT162b2 for patients with cancer: interim analysis of a prospective observational study
Leticia Monin et al.
LANCET ONCOLOGY (2021)
Impaired Humoral Response in Renal Transplant Recipients to SARS-CoV-2 Vaccination with BNT162b2 (Pfizer-BioNTech)
Johannes Korth et al.
VIRUSES-BASEL (2021)
Interim Estimates of Vaccine Effectiveness of Pfizer-BioNTech and Moderna COVID-19 Vaccines Among Health Care Personnel-33 US Sites, January-March 2021
Tamara Pilishvili et al.
MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT (2021)
Increased viral variants in children and young adults with impaired humoral immunity and persistent SARS-CoV-2 infection: A consecutive case series
Thao T. Truong et al.
EBIOMEDICINE (2021)
BNT162b2 COVID-19 vaccine is significantly less effective in patients with hematologic malignancies
Katrin Herzog Tzarfati et al.
AMERICAN JOURNAL OF HEMATOLOGY (2021)
Impaired anti-SARS-CoV-2 humoral and cellular immune response induced by Pfizer-BioNTech BNT162b2 mRNA vaccine in solid organ transplanted patients
Monica Miele et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2021)
Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in adult patients with autoimmune inflammatory rheumatic diseases and in the general population: a multicentre study
Victoria Furer et al.
ANNALS OF THE RHEUMATIC DISEASES (2021)
Disease activity and humoral response in patients with inflammatory rheumatic diseases after two doses of the Pfizer mRNA vaccine against SARS-CoV-2
Yolanda Braun-Moscovici et al.
ANNALS OF THE RHEUMATIC DISEASES (2021)
Methotrexate hampers immunogenicity to BNT162b2 mRNA COVID-19 vaccine in immune-mediated inflammatory disease
Rebecca H. Haberman et al.
ANNALS OF THE RHEUMATIC DISEASES (2021)
Impaired humoral responses to COVID-19 vaccination in patients with lymphoma receiving B-cell-directed therapies
Paola Ghione et al.
BLOOD (2021)
Poor humoral and T-cell response to two-dose SARS-CoV-2 messenger RNA vaccine BNT162b2 in cardiothoracic transplant recipients
Rene Schramm et al.
CLINICAL RESEARCH IN CARDIOLOGY (2021)
Neutralising capacity against Delta (B.1.617.2) and other variants of concern following Comirnaty (BNT162b2, BioNTech/Pfizer) vaccination in health care workers, Israel
Yaniv Lustig et al.
EUROSURVEILLANCE (2021)
Effectiveness of SARS-CoV-2 Vaccination in a Veterans Affairs Cohort of Patients With Inflammatory Bowel Disease With Diverse Exposure to Immunosuppressive Medications
Nabeel Khan et al.
GASTROENTEROLOGY (2021)
Confronting the Delta Variant of SARS-CoV-2, Summer 2021
Carlos del Rio et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2021)
Immunogenicity of BNT162b2 mRNA COVID-19 vaccine and SARS-CoV-2 infection in lung transplant recipients
Jan Havlin et al.
JOURNAL OF HEART AND LUNG TRANSPLANTATION (2021)
Antibody and T Cell Response to SARS-CoV-2 Messenger RNA BNT162b2 Vaccine in Kidney Transplant Recipients and Hemodialysis Patients
Dominique Bertrand et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2021)
Humoral Response after SARS-CoV-2 mRNA Vaccination in a Cohort of Hemodialysis Patients and Kidney Transplant Recipients
Clement Danthu et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2021)
BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans
Ugur Sahin et al.
NATURE (2021)
High immunogenicity of a messenger RNA-based vaccine against SARS-CoV-2 in chronic dialysis patients
Nathalie Longlune et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION (2021)
Three Doses of an mRNA Covid-19 Vaccine in Solid-Organ Transplant Recipients
Nassim Kamar et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Antibody response to inactivated COVID-19 vaccine (CoronaVac) in immune-mediated diseases: a controlled study among hospital workers and elderly
Emire Seyahi et al.
RHEUMATOLOGY INTERNATIONAL (2021)
Serological response to COVID-19 vaccination in patients with cancer older than 80 years
Daniela Iacono et al.
JOURNAL OF GERIATRIC ONCOLOGY (2021)
Immunogenicity of the BNT162b2 COVID-19 mRNA vaccine and early clinical outcomes in patients with haematological malignancies in Lithuania: a national prospective cohort study
Kazimieras Maneikis et al.
LANCET HAEMATOLOGY (2021)
Antibody responses after SARS-CoV-2 vaccination in patients with lymphoma
Sean H. Lim et al.
LANCET HAEMATOLOGY (2021)
Sustained Effectiveness of Pfizer-BioNTech and Moderna Vaccines Against COVID-19 Associated Hospitalizations Among Adults — United States, March–July 2021
Mark W. Tenforde et al.
MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT (2021)
COVID-19 in immunocompromised populations: implications for prognosis and repurposing of immunotherapies
Jason D. Goldman et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2021)
Impaired humoral immunity to SARS-CoV-2 BNT162b2 vaccine in kidney transplant recipients and dialysis patients
Hector Rincon-Arevalo et al.
SCIENCE IMMUNOLOGY (2021)
Vaccine response following anti-CD20 therapy: a systematic review and meta-analysis of 905 patients
Abi Vijenthira et al.
BLOOD ADVANCES (2021)
Impaired Antibody Response to the BNT162b2 Messenger RNA Coronavirus Disease 2019 Vaccine in Patients With Systemic Lupus Erythematosus and Rheumatoid Arthritis
Christian Ammitzboll et al.
ACR OPEN RHEUMATOLOGY (2021)
Impaired humoral and cellular immunity after SARS-CoV-2 BNT162b2 (tozinameran) prime-boost vaccination in kidney transplant recipients
Arne Sattler et al.
JOURNAL OF CLINICAL INVESTIGATION (2021)
Serological Assays Estimate Highly Variable SARS-CoV-2 Neutralizing Antibody Activity in Recovered COVID-19 Patients
Larry L. Luchsinger et al.
JOURNAL OF CLINICAL MICROBIOLOGY (2020)
Case Study: Prolonged Infectious SARS-CoV-2 Shedding from an Asymptomatic Immunocompromised Individual with Cancer
Victoria A. Avanzato et al.
CELL (2020)
Shedding of Viable SARS-CoV-2 after Immunosuppressive Therapy for Cancer
Teresa Aydillo et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Accuracy of Administrative Code Data for the Surveillance of Healthcare-Associated Infections: A Systematic Review and Meta-Analysis
Michihiko Goto et al.
CLINICAL INFECTIOUS DISEASES (2014)
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement
David Moher et al.
PLOS MEDICINE (2009)
Bivariate analysis of sensitivity and specificity produces informative summary measures in diagnostic reviews
JB Reitsma et al.
JOURNAL OF CLINICAL EPIDEMIOLOGY (2005)
A systematic review of quasi-experimental study designs in the fields of infection control and antibiotic resistance
AD Harris et al.
CLINICAL INFECTIOUS DISEASES (2005)
Meta-analysis of observational studies in epidemiology - A proposal for reporting
DF Stroup et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2000)